Tos Salem M, Hajikarimloo Bardia, Osama Mahmoud, Mantziaris Georgios, Adeeb Nimer, Kandregula Sandeep, Salim Hamza Adel, Musmar Basel, Ogilvy Christopher, Kondziolka Douglas, Dmytriw Adam A, El Naamani Kareem, Abdelsalam Ahmed, Kumbhare Deepak, Gummadi Sanjeev, Ataoglu Cagdas, Essibayi Muhammed Amir, Erginoglu Ufuk, Keles Abdullah, Muram Sandeep, Sconzo Daniel, Riina Howard, Rezai Arwin, Pöppe Johannes, Sen Rajeev D, Alwakaa Omar, Griessenauer Christoph J, Jabbour Pascal, Tjoumakaris Stavropoula I, Burkhardt Jan-Karl, Starke Robert M, Baskaya Mustafa K, Sekhar Laligam N, Levitt Michael R, Altschul David J, Haranhalli Neil, McAvoy Malia, Abushehab Abdallah, Aslan Assala, Swaid Christian, Abla Adib, Stapleton Christopher, Koch Matthew, Srinivasan Visish M, Chen Peng R, Blackburn Spiros, Cochran Joseph, Choudhri Omar, Pukenas Bryan, Orbach Darren, Smith Edward, Möhlenbruch Markus, Alaraj Ali, Aziz-Sultan Ali, Dlouhy Kathleen, El Ahmadieh Tarek, Patel Aman B, Savardekar Amey, Cuellar Hugo H, Lawton Michael, Guthikonda Bharat, Morcos Jacques, Sheehan Jason
Department of Neurosurgery, University of Virginia, Charlottesville, VA, United States.
Department of Neurosurgery, Louisiana State University Health Science Center, Shreveport, LA, United States; Department of Neurosurgery, UT Health Sciences Center at Houston, McGovern Medical School, Houston, TX, United States.
Clin Neurol Neurosurg. 2025 Feb;249:108669. doi: 10.1016/j.clineuro.2024.108669. Epub 2024 Dec 3.
Spetzler-Martin (SM) Grade III brain arteriovenous malformations (BAVMs) represent a transitional risk zone between low- and high-grade BAVMs, characterized by diverse angioarchitecture. The primary treatment options are endovascular embolization, microsurgical resection (MS), and stereotactic radiosurgery (SRS). This study compares the efficacy and outcomes of MS and SRS.
We conducted a multicenter, retrospective study involving patients from the MISTA database with SM Grade III BAVMs treated with MS or SRS between 2010 and 2023. Propensity matching was based on age, favorable modified Rankin Score (mRS) at presentation, nidus size, rupture status, location depth, and eloquence.
After matching, 60 patients were equally divided between MS and SRS groups. Median age (MS: 45.0 vs. SRS: 42.5 years, p = 0.3) and AVM size (MS: 3.2 vs. SRS: 2.9 cm, p = 0.6) were similar. MS showed higher obliteration rates (93.3 %) compared to SRS (46.7 %) at the last follow-up (p < 0.001). The median time to obliteration post-SRS was 31.5 months (IQR: 15.3-60.0). SRS obliteration rates were 19 %, 29 %, and 59 % at 24, 36, and 60 months, respectively. Overall complication rates (MS: 30 % vs. SRS: 20 %, p = 0.4) and permanent complications (MS: 10 % vs. SRS: 13.3 %, p > 0.9) were similar. Hemorrhage occurred once in the MS group and none in the SRS (p > 0.9). Favorable outcomes (mRS 0-2) were higher with SRS than MS (93.3 % vs 80.0 %, p = 0.3), with one AVM-related mortality in the MS group.
MS and SRS are viable treatments for SM Grade III BAVMs. Treatment choice should be individualized by a multidisciplinary team, considering patient goals.
史匹兹勒-马丁(SM)Ⅲ级脑动静脉畸形(BAVM)代表低级别和高级别BAVM之间的过渡风险区域,其血管构筑多样。主要治疗选择包括血管内栓塞、显微手术切除(MS)和立体定向放射外科治疗(SRS)。本研究比较了MS和SRS的疗效及结果。
我们进行了一项多中心回顾性研究,纳入了2010年至2023年间来自MISTA数据库中接受MS或SRS治疗的SMⅢ级BAVM患者。倾向匹配基于年龄、就诊时改良Rankin评分(mRS)良好、病灶大小、破裂状态、位置深度和功能区情况。
匹配后,MS组和SRS组各有60例患者。中位年龄(MS组:45.0岁 vs. SRS组:42.5岁,p = 0.3)和AVM大小(MS组:3.2 cm vs. SRS组:2.9 cm,p = 0.6)相似。末次随访时,MS组的闭塞率(93.3%)高于SRS组(46.7%)(p < 0.001)。SRS术后闭塞的中位时间为31.5个月(IQR:15.3 - 60.0)。SRS在24、36和60个月时的闭塞率分别为19%、29%和59%。总体并发症发生率(MS组:30% vs. SRS组:20%,p = 0.4)及永久性并发症发生率(MS组:10% vs. SRS组:13.3%,p > 0.9)相似。MS组发生1次出血,SRS组无出血发生(p > 0.9)。SRS组的良好结局(mRS 0 - 2)高于MS组(93.3% vs 80.0%,p = 0.3),MS组有1例与AVM相关的死亡。
MS和SRS都是治疗SMⅢ级BAVM的可行方法。治疗选择应由多学科团队根据患者目标进行个体化决定。